Home » Stocks » ABBV

AbbVie Inc. (ABBV)

Stock Price: $109.03 USD 0.42 (0.39%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
After-hours: $108.95 -0.08 (-0.07%) Apr 20, 7:57 PM
Market Cap 192.42B
Revenue (ttm) 45.80B
Net Income (ttm) 4.62B
Shares Out 1.67B
EPS (ttm) 2.72
PE Ratio 40.08
Forward PE 8.70
Dividend $4.84
Dividend Yield 4.44%
Trading Day April 20
Last Price $109.03
Previous Close $108.61
Change ($) 0.42
Change (%) 0.39%
Day's Open 108.12
Day's Range 108.05 - 109.56
Day's Volume 5,411,835
52-Week Range 76.17 - 111.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The stock market's dividend yield is at a 10-year low, but these five companies still yield over 2%.

Other stocks mentioned: CVX, JNJ, KO, PG
13 hours ago - The Motley Fool

Four drugmakers helped cause the deadly U.S. opioid epidemic by deceptively marketing their drugs and downplaying their addictive risks, a lawyer for several California counties argued on Monday at the ...

Other stocks mentioned: JNJ, ENDP, TEVA
1 day ago - Reuters

AbbVie (ABBV) closed at $108.61 in the latest trading session, marking a +0.65% move from the prior day.

1 day ago - Zacks Investment Research

Is it possible for investors to find cheap stocks that have double digit growth and that also pay a great dividend yield?

Other stocks mentioned: ATCO, MDC, TROW, WSBC
5 days ago - Zacks Investment Research

Attractive dividend yields and solid businesses make these stocks stand out.

Other stocks mentioned: BEP, EPD
5 days ago - The Motley Fool

Worried about sky-high valuations? Check out these two pharma stocks.

Other stocks mentioned: PFE
6 days ago - The Motley Fool

See why the world's most acclaimed value investor is investing in these three stocks.

Other stocks mentioned: BMY, MRK
6 days ago - The Motley Fool

There's more reason to be concerned than in the past.

6 days ago - The Motley Fool

AbbVie (ABBV) closed at $108.22 in the latest trading session, marking a -0.03% move from the prior day.

1 week ago - Zacks Investment Research

Rinvoq's FDA approval decision could be a sign the drug class is under investigation.

1 week ago - The Motley Fool

Their high yields and history of success bode well for the long term.

Other stocks mentioned: PFE
1 week ago - The Motley Fool

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

1 week ago - Zacks Investment Research

AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 week ago - Zacks Investment Research

Is (ABBV) Outperforming Other Medical Stocks This Year?

1 week ago - Zacks Investment Research

Expect solid sales growth through the next year or two.

1 week ago - The Motley Fool

These stocks check off all the boxes for dividend-seeking investors.

Other stocks mentioned: BEP, PFE
1 week ago - The Motley Fool

Look at more than just the valuation metrics.

Other stocks mentioned: VTRS
1 week ago - The Motley Fool

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Other stocks mentioned: ACAD, ALXN, AZN, BIIB, BNTX, CRSP, EDIT ...
1 week ago - Investors Business Daily

AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Skyrizi - psoriatic arthritis.

1 week ago - Zacks Investment Research

Now let's jump into three stocks that investors might want to buy now amid the bullish start to the second quarter.

Other stocks mentioned: AAPL, JPM, MSFT, NFLX, NOW, SPOT, TSLA
1 week ago - Zacks Investment Research

Netflix and Facebook are among the top stocks for April. Q.ai's Artificial Intelligence has also dug up top tech stocks, top consumer stocks, top quality value stocks, and top growth stocks.

Other stocks mentioned: ADBE, FB, GM, KLAC, NFLX, NKE, OMC ...
1 week ago - Forbes

AbbVie Inc (NYSE: ABBV) has submitted marketing applications to the FDA and European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab-rzaa, 150 mg) for the treatment of adults with acti...

1 week ago - Benzinga

NORTH CHICAGO, Ill., April 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for SKYRIZI® (risankizumab-rzaa, 150 mg) to the U.S. Food and D...

1 week ago - PRNewsWire

NORTH CHICAGO, Ill., April 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN...

1 week ago - PRNewsWire

Horizon Therapeutics has a clear path to significant sales growth.

Other stocks mentioned: BMY, HZNP, PFE, SGEN, VRTX
1 week ago - The Motley Fool

Shares of AbbVie have climbed more than 22% over the past 12 months, but there's still room to grow.

2 weeks ago - The Motley Fool

The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.

2 weeks ago - Zacks Investment Research

The FDA has extended the review period for AbbVie Inc's (NYSE: ABBV) supplemental marketing application seeking upadacitinib approval to treat adults and adolescents with moderate to severe atopic derma...

2 weeks ago - Benzinga

This is why America's largest pharmaceutical companies are nervous about the American Jobs Plan.

Other stocks mentioned: JNJ
2 weeks ago - The Motley Fool

NORTH CHICAGO, Ill., April 2, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has e...

2 weeks ago - PRNewsWire

IRVINE, Calif., April 1, 2021 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of SkinMedica ® Neck Correct Cream, the first product from the professional...

2 weeks ago - PRNewsWire

NORTH CHICAGO, Ill., April 1, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluati...

2 weeks ago - PRNewsWire

NORTH CHICAGO, Ill., March 31, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2021 financial results on Friday, April 30, 2021, before the market opens.

2 weeks ago - PRNewsWire

This stock has it all.

2 weeks ago - The Motley Fool

You may be surprised that not all cannabis stocks are focused entirely on weed. Here are some diversified companies to consider.

Other stocks mentioned: IIPR, PFE, SMG, STZ, VFF, YCBD
3 weeks ago - InvestorPlace

The FDA has accepted for review AbbVie Inc's (NYSE: ABBV) marketing application seeking approval for Atogepant for the preventive treatment of migraine in adults who meet the criteria for episodic migra...

3 weeks ago - Benzinga

NORTH CHICAGO, Ill., March 30, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for atogepant, an inv...

3 weeks ago - PRNewsWire

AbbVie (ABBV) closed the most recent trading day at $106.73, moving +0.71% from the previous trading session.

3 weeks ago - Zacks Investment Research

It's a big-name pharma with a storied history, but Eli Lilly still has plenty of room left to run.

Other stocks mentioned: BMY, JNJ, LLY, PFE, SPY, VHT
3 weeks ago - The Motley Fool

You don't have to sacrifice growth for great dividend yields with these stocks.

Other stocks mentioned: EPD, PFE
3 weeks ago - The Motley Fool

Pharmaceutical stocks with stable, substantial dividends can hold their own in almost any environment, making them ideal for long-term income investors.

Other stocks mentioned: AMGN, BMY, GILD, JNJ, LLY, SNY
3 weeks ago - Kiplinger

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

3 weeks ago - Zacks Investment Research

With March almost over, many investors are looking to the second quarter and beyond.

Other stocks mentioned: CAH, CVX, T, WBA
3 weeks ago - 24/7 Wall Street

Value stocks aren't always a sure thing despite their reassuring metrics. These seven seem to be close to it though.

Other stocks mentioned: AAPL, ATO, GE, GM, JPM, MSFT
3 weeks ago - InvestorPlace

AbbVie (ABBV) closed at $104.84 in the latest trading session, marking a -1% move from the prior day.

4 weeks ago - Zacks Investment Research

The stock of AbbVie (NYSE:ABBV, 30-year Financials) appears to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock sho...

4 weeks ago - GuruFocus

Final Trades: Roku, Lam Research, AbbVie & more

YouTube video

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: LRCX, ROKU, JBHT, TLT
4 weeks ago - CNBC Television

With yields ranging between 5% and 10%, billionaire money managers are raking in some serious income with these companies.

Other stocks mentioned: NLY, T
4 weeks ago - The Motley Fool

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc.("AbbVie" or the "Company") (NYSE: ABBV). Such investors are advised to...

4 weeks ago - Newsfile Corp

Income-seeking investors will love these stocks with great dividends and attractive valuations.

Other stocks mentioned: BMY, VTRS
4 weeks ago - The Motley Fool

About ABBV

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, mar... [Read more...]

Industry
Drug Manufacturers-General
CEO
Richard Gonzalez
Employees
47,000
Stock Exchange
NYSE
Ticker Symbol
ABBV
Full Company Profile

Financial Performance

In 2020, AbbVie's revenue was $45.80 billion, an increase of 37.69% compared to the previous year's $33.27 billion. Earnings were $4.62 billion, a decrease of -41.44%.

Financial Statements

Analyst Forecasts

According to 22 analysts, the average rating for AbbVie stock is "Buy." The 12-month stock price forecast is 122.17, which is an increase of 12.05% from the latest price.

Price Target
$122.17
(12.05% upside)
Analyst Consensus: Buy